CoChat
Sign Up
Cited by 231Atrial Fibrillation Management and OutcomesHeart Failure Treatment and ManagementVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation

Open access
Hijazi, Ziad, Wallentin, Lars, Siegbahn, Agneta, Andersson, Ulrika, Christersson, Christina, Ezekowitz, Justin, Gersh, Bernard J., Hanna, Michael, Hohnloser, Stefan, Horowitz, John, Huber, Kurt, Hylek, Elaine M., Lopes, Renato D., McMurray, John J.V., Granger, Christopher B.·2013·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2012.11.082
Open this paper in CoChat — free accountOpen PDF

Abstract

Objectives This study sought to assess the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial, and the treatment effect of apixaban according to NT-proBNP levels.Background Natriuretic peptides are associated with mortality and cardiovascular events in several cardiac diseases.Methods In the ARISTOTLE trial, 18,201 patients with AF were randomized to apixaban or warfarin. Plasma samples at randomization were available from 14,892 patients. The association between NT-proBNP concentrations and clinical outcomes was evaluated using Cox proportional hazard models, after adjusting for established cardiovascular risk factors.Results Quartiles of NT-proBNP were: Q1, ≤363 ng/l; Q2, 364 to 713 ng/l; Q3, 714 to 1,250 ng/l; and Q4, >1,250 ng/l. During 1.9 years, the annual rates of stroke or systemic embolism ranged from 0.74% in the bottom NT-proBNP quartile to 2.21% in the top quartile, an adjusted hazard ratio of 2.35 (95% confidence interval [CI]: 1.62 to 3.40; p < 0.0001). Annual rates of cardiac death ranged from 0.86% in Q1 to 4.14% in Q4, with an adjusted hazard ratio of 2.50 (95% CI: 1.81 to 3.45; p < 0.0001). Adding NT-proBNP levels to the CHA2DS2VASc score improved C-statistics from 0.62 to 0.65 (p = 0.0009) for stroke or systemic embolism and from 0.59 to 0.69 for cardiac death (p < 0.0001). Apixaban reduced stroke, mortality, and bleeding regardless of the NT-proBNP level.Conclusions NT-proBNP levels are often elevated in AF and independently associated with an increased risk of stroke and mortality. NT-proBNP improves risk stratification beyond the CHA2DS2VASc score and might be a novel tool for improved stroke prediction in AF. The efficacy of apixaban compared with warfarin is independent of the NT-proBNP level. (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation [ARISTOTLE]; NCT00412984).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2012.11.082

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

Sorted by citations

Items 201–228 of 228

Related

See all

Metadata

Authors
Hijazi, Z., Wallentin, L., Siegbahn, A., Andersson, U., Christersson, C., Ezekowitz, J., Gersh, B. J., Hanna, M., Hohnloser, S., Horowitz, J., Huber, K., Hylek, E. M., Lopes, R. D., McMurray, J. J. V., & Granger, C. B.
Affiliations
  • Uppsala University (SE)
  • University of Alberta (CA)
  • Mayo Clinic (US)
  • Bristol-Myers Squibb (United States) (US)
  • Goethe University Frankfurt (DE)
  • The University of Adelaide (AU)
  • Wilhelminen Hospital (AT)
  • Boston University (US)
  • Western Infirmary (GB)
  • Duke Medical Center (US)
Corresponding author
Hijazi, Ziad
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2013-06
Volume
61
Issue
22
Pages
2274-2284
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2012.11.082
OpenAlex
W189243586
Cited by
231
References
39
Citations by year
2026: 6 · 2025: 12 · 2024: 17 · 2023: 21 · 2022: 14 · 2021: 15 · 2020: 19 · 2019: 23 · 2018: 22 · 2017: 22 · 2016: 27 · 2015: 11 · 2014: 14 · 2013: 8
FWCI
13.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Bank (Australian Catholic University) (submittedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Funders
  • Bristol-Myers Squibb, Co.
  • Pfizer Inc.
  • Bristol-Myers Squibb Co.
  • Boehringer-Ingelheim
  • AstraZeneca, Merck/Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline
  • AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Schering-Plough
  • Boehringer-Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Schering-Plough/Merck
  • AstraZeneca and Boehringer-Ingelheim
  • Bristol-Myers Squibb/Pfizer
  • Alere, AstraZeneca, Amgen, Abbott, Servier, Johnson &amp; Johnson, Pfizer, and Bristol-Myers Squibb
  • sanofi-aventis, St. Jude Medical, Boehringer-Ingelheim, Cardiome, Pfizer, Bayer, and Bristol-Myers Squibb
  • sanofi-aventis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, Medtronic, and St. Jude Medical
  • Bristol-Myers Squibb and Pfizer
  • AstraZeneca, Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Bayer, Daiichi Sankyo, and sanofi-aventis
  • Johnson &amp; Johnson, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, and Ortho-McNeil-Janssen
  • Boehringer Ingelheim and Bayer
  • Bristol-Myers Squibb, AstraZeneca, Boehringer-Ingelheim, and Daiichi Sankyo
  • Bristol-Myers Squibb and Boehringer-Ingelheim
  • Bristol-Myers Squibb, Boehringer-Ingelheim, Astellas, AstraZeneca, GlaxoSmithKline, Medtronic Foundation, Merck, sanofi-aventis, and the Medicines Company
  • Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, AstraZeneca, Eli Lily, GlaxoSmithKline, Hoffman-La Roche, Novartis, Otsuka, Sanofi-Aventis, and the Medicines Company
  • Pfizer, Novartis, Otsuka, and Hoffmann-La Roche
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
atrial fibrillation, apixaban, stroke risk stratification, CHA2DS2-VASc score, cardiovascular mortality, systemic embolism, risk prediction, ARISTOTLE trial, warfarin, bleeding risk, biomarkers, prognosis, natriuretic peptides, cardiovascular risk
MeSH terms
Aged, Anticoagulants, Atrial Fibrillation, Embolism, Female, Fibrinolytic Agents, Humans, Male, Peptide Fragments, Prognosis, Pyrazoles, Pyridones, Warfarin, Biomarkers, Multivariate Analysis, Proportional Hazards Models, Risk Assessment, Natriuretic Peptide, Brain, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review